-
Mashup Score: 28
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Sodium–glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology - 9 month(s) ago
Sodium–glucose co-transporter-2 inhibitors (SGLT2is; canagliflozin, empagliflozin, dapagliflozin, ertugliflozin and sotagliflozin), also referred to as ‘glifloz
Source: academic.oup.comCategories: Hematologists1, Latest HeadlinesTweet-
SGLT-2i use is ubiquitous AND erythrocytosis. Careful eval of erythrocytosis is advised. Sodium–glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology https://t.co/5lQHgGmX2Z #mpnsm #diabetes #ckd #chf @NDTsocial
-
-
Mashup Score: 3Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm - 9 month(s) ago
Blood Cancer Journal – Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Check out our current treatment approach to MPN-BP https://t.co/o9Kx0NuxtD #tefferi #mpnsm @MayoCancerCare @VincentRK @AlkaliDr @doctorpemm @MrinalPatnaik @BloodCancerJnl https://t.co/i3TjwfCaeP
-
-
Mashup Score: 2
Between October 2007 and July 2013, 183 Mayo Clinic patients (median age 65 years; 58% males) with high/intermediate risk myelofibrosis (MF) were enrolled in consecutive phase 1/2 JAK2 inhibitor (JAKi) clinical trials with momelotinib (n = 79), ruxolitinib (n = 50), fedratinib (n = 23) and BMS-911543 (n = 31). Using conventional criteria, the respective response rates for spleen and…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
JAKi for myelofibrosis: Long term survival and predictors of response https://t.co/4V83S8UN9w @MayoCancerCare @BloodCancerJnl @MPN_RF @AlkaliDr @VincentRK @MayoClinic #mpnsm https://t.co/aLyDt3g2Ly
-
-
Mashup Score: 0ASH-FDA Collaboration: Workshop on Regulatory Science in Hematology | ASH News Daily | American Society of Hematology - 1 year(s) ago
ASH, in collaboration with the U.S. Food and Drug Administration (FDA), held its inaugural workshop on regulatory science in hematology at ASH headquarters in Washington, DC. The workshop took place in late October and was co-chaired by Dr. Grzegorz Nowakowski, vice chair of the ASH Clinical Trial Innovation Subcommittee, and Dr. Richard Pazdur, director of the FDA’s Oncology Center of…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
All you need to know about the inaugural ASH-FDA workshop held Oct 2022. #ASH22 @ASH_hematology @GregNowakowski Recap by @YiLinMDPhD in Sunday’s ASH News Daily https://t.co/SUfxIkS8K9 https://t.co/UaiZrBV3NV
-
-
Mashup Score: 0
Skip Nav Destination December 13, 2021 David Steensma, MD Content License:Private Click the image below to download and print the PDF of this year’s Hematology Crossword, created by Dr. David Steensma, and…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
In case you missed the quintessential #ASH22 crossword by @DavidSteensma here is the link https://t.co/QzuDW1FOVE @DavidSteensma @ASH_hematology https://t.co/1boAf9fZmq
-
-
Mashup Score: 0Breaking mAb: a Novel Monoclonal Antibody Takes Aim at Mutant Calreticulin | ASH News Daily | American Society of Hematology - 1 year(s) ago
Lymphoma has rituximab. Myeloma has daratumumab. Myeloproliferative neoplasms (MPN) have … let’s see, let me think now, oh — they have nothing. Absolutely no “-mAb” of any kind. Monoclonal antibodies (mAb) have entered the modern therapeutics chat in a big way, at times even dominating the forum, in all hematology spaces covering classical to malignant. Both researchers and clinicians in the…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Breaking mab elegant piece by @NatashaSzuber #ASHNewsDaily #Mondayissue Learn all about the CALR directed antibody.. novel immuno targeted therapy approach to #mpnsm #ASH22 @ASH_hematology @MPN_RF @MPN_Hub https://t.co/DO6ZESMRVE
-
-
Mashup Score: 2
Imagine a better tomorrow … or, for the hematologists out there, should I say, a better to-marrow? With groundbreaking acceleration in bone marrow research and discovery, we are on the cusp of great advances in the diagnosis and treatment of primary bone marrow disorders. As underscored by the Education Spotlight Sessions at this year’s meeting, the future looks especially bright for those with a…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Here’s hoping for “A Better To-Marrow” Please check out #ASH22 education spotlight preview by @D_Hermel @ASH_hematology #bmfsm #histiocytes #DEI #clinical trials #Immunotherapy #ASHNewsDaily https://t.co/NG31KM3u7c
-
-
Mashup Score: 7To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia - 2 year(s) ago
Blood Cancer Journal – To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Very important study on HRQol benefits with venetoclax combinations in AML by @PratzKW Need to incorporate Qol in routine practice. Check out the accompanying editorial. https://t.co/a7QTzcmAFs @BloodCancerJnl @doctorpemm @AaronGoodman33 @AlkaliDr @MrinalPatnaik #leusm https://t.co/nviKou7JE0 https://t.co/Ahwuya45EH
-
-
Mashup Score: 21.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events - 2 year(s) ago
Naseema Gangat, Natasha Szuber, Yamna Jadoon, Faiqa Farrukh, Kebede Begna, Michelle A Elliott, Alexandra P Wolanskyj-Spinner, Curtis A. Hanson, Animesh D Pardan
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
What’s in a Number? Platelet count over 1.5 million in ET @MayoCancerCare @BloodAdvances @ASH_hematology @MPN_Hub @MPN_RF #mpnsm 1.5 million platelet count limit at essential thrombocythemia diagnosis: correlations and relevance to vascular events https://t.co/op4OpBbtER
-
A real tour d’horizon on chronic neutrophilic leukemia by @NatashaSzuber #mpnsm #cnl #leuksm @AjHematology @VincentRK American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/IjHb2E2dF4